Statins: panacea for sepsis? (Q36428724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Statins: panacea for sepsis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Yaniv Almog

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Robert S Rosenson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Terry S Smith

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Daniel G Hackam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

242-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Sepsis: current status, future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Role of NFkappaB in the mortality of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The epidemiology of sepsis in the United States from 1979 through 2000

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Current epidemiology of septic shock: the CUB-Réa Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Septic shock, multiple organ failure, and acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Patient characteristics and costs of severe sepsis and septic shock in Quebec

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Drug intervention trials in sepsis: divergent results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Beyond lipid lowering: the role of statins in vascular protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Antiinflammatory and immunomodulatory properties of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Inhibition of monocyte chemotactic protein-1 synthesis by statins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin blunts endotoxin-induced tissue factor in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Lymphocyte function antigen-1 mediates leukocyte adhesion and subsequent liver damage in endotoxemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Inhibition of proinflammatory cytokine production by pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in pri

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin decreases aldehyde production derived from lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Cellular antioxidant effects of atorvastatin in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Superoxide anion overproduction in sepsis: effects of vitamin e and simvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Neuroprotection mediated by changes in the endothelial actin cytoskeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin treatment after onset of sepsis in a murine model improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins inhibit HIV-1 infection by down-regulating Rho activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Prior statin therapy is associated with a decreased rate of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The effect of statins on mortality in patients with bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin therapy prior to ICU admission: protection against infection or a severity marker?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin therapy is associated with fewer deaths in patients with bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Total cholesterol and risk of mortality in the oldest old.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statins, inflammation, and sepsis: hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Risk of nosocomial infections and effects of total cholesterol, HDL cholesterol in surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Cholesterol and serum albumin levels as predictors of cross infection, death, and length of hospital stay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Outcomes in 45 patients with statin-associated myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin-associated neuromyotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin-associated exacerbation of myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Four cases of tendinopathy in patients on statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Statin-associated peripheral neuropathy: review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Lupus-like syndrome associated with statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

Disorder resembling Guillain-Barré syndrome on initiation of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970439-X

7 January 2021

10.1016/S1473-3099(06)70439-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16554249%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference